Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 3Myeloid 3Sarcoma 2Gastrointestinal 2Lymphoid 1Dermatologic 1Classical hematology 1

Conditions

Gastrointestinal Stromal Tumors 2Digestive System Neoplasms 1

Interventions

Specimen Handling 14Magnetic Resonance Spectroscopy 14Doxorubicin 11Cyclophosphamide 11Biopsy 9Radiation 8atezolizumab 7Temozolomide 7X-Rays 6Vincristine 6Nivolumab 6Etoposide 6Bevacizumab 6liposomal doxorubicin 5fludarabine 5cabozantinib 5Sirolimus 5Radiotherapy 5Phantoms, Imaging 5Irinotecan 5Immunoglobulin G 5Ifosfamide 5Disulfides 5pembrolizumab 4Nuclear Medicine Department, Hospital 4temsirolimus 3palbociclib 3olaparib 3fludarabine phosphate 3Surgical Procedures, Operative 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Imatinib Mesylate × Sarcoma × 30 days × Clear all
NCT07171203 2026-05-27

Preoperative Imatinib and Fampridine in KIT Mutant Gastrointestinal Stromal Tumor

University of California, San Diego

Phase 1 Recruiting
18 enrolled
GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT07406633 2026-05-19

KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GIST in 1st Line Setting

Kumquat Biosciences Inc.

Phase 2 Recruiting
46 enrolled
GastrointestinalSarcoma

Digestive System Neoplasms, Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡